Intravitreal Bevacizumab for Choroidal Neovascularization Attributable to Pathological Myopia: One-Year Results

Ikuno, Yasushi; Sayanagi, Kaori; Soga, Kaori; Sawa, Miki; Tsujikawa, Motokazu; Gomi, Fumi; Tano, Yasuo

doi:10.1016/j.ajo.2008.07.017

Cited by 150 publications

(123 citation statements)

References 28 publications

Supporting

Mentioning

111

Contrasting

Unclassified

Order By: Relevance

“…Recently, lower dose levels of 1 and 1.25 mg intravitreous bevacizumab were reported and had favourable results in 1-year follow-up. 8,9 However, more frequent injections were noted. Further studies for comparing the frequency of injections using different dose levels are necessary.…”

Section: Discussionmentioning

confidence: 99%

Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up

Chen

2009

Eye

View full text Add to dashboard Cite

Purpose To evaluate the safety and efficacy of intravitreal bevacizumab in Chinese patients with choroidal neovascularization (CNV) secondary to pathologic myopia. Methods Eight eyes of consecutive patients with myopic CNV without earlier treatment were treated with intravitreal injection of bevacizumab (2.5 mg). All patients underwent a clinical examination, which included visual acuity measurements, fundus photography, fluorescein angiography, and optical coherence tomography. Results Eight eyes of eight patients with ages ranging from 26 to 62 years (mean 41.5 years) were enroled. The follow-up period ranged from 13 to 17 months (mean, 14.9 months). At the 12-month follow-up, vision had improved in all eyes by three or more lines. However, a new-onset CNV adjacent to the earlier lesion and visual loss of one line at the 16th month were observed in one eye. The mean VA had significantly improved from the baseline value 20/82 to 20/25 (P ¼ 0.017). The final mean central retinal thickness was 214.1 ± 36.3 lm, with a mean decrease of 59.8 lm from the pretreatment value (P ¼ 0.017). The mean number of injections was 1.4 (ranging from 1 to 2) within 12 months. No other ocular or systemic side effects were noted. Conclusions In this small series of patients with 1-year follow-up, intravitreal injection of 2.5 mg bevacizumab seems to be effective and safe in patients with myopic CNV.

show abstract

Section: Discussionmentioning

confidence: 99%

Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up

Chen

2009

Eye

View full text Add to dashboard Cite

show abstract

“…Those findings have led toward wider use of anti-VEGF agent in these disorders (Ikuno et al 2009;Gharbiya et al 2010). Other studies have shown potential benefit of bevacizumab in treatment of CNVM related to angioid streaks and ocular inflammatory diseases (Mansour et al 2009;Wiegand et al 2009).…”

Section: Choroidal Neovascularization In Other Diseasesmentioning

confidence: 99%

Antiangiogenic Therapy for Ischemic Retinopathies

Al-Latayfeh¹,

Silva²,

Sun³

et al. 2012

Cold Spring Harbor Perspectives in Medicine

View full text Add to dashboard Cite

“…[21][22][23] Treatment outcomes after intravitreal bevacizumab in 15 studies are summarised in Table 1. [24][25][26][27][28][29][30][31][32][33][34][35][36][37][38] A cumulative analysis of all study data reveals the following trends. Of all studies examined, a total of 181 eyes received treatment for naïve lesions, and 74 eyes were treated earlier.…”

Section: Pathological Myopiamentioning

confidence: 99%

“…There were few reported complications; there was only one case each of retinal detachment, 28 RPE rip, 24 and low grade iridocyclitis. 30 These pooled 12-month data suggest that visual outcomes with bevacizumab treatment are better than other available options for myopic CNV.…”

mentioning

confidence: 99%

Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration

Gupta

Elagouz

Sivaprasad

2009

Eye

View full text Add to dashboard Cite

Choroidal neovascularisation (CNV) is characterised by new blood vessel growth under the retina that usually results in significant visual impairment when the fovea is involved. Though CNV is more commonly associated with age-related macular degeneration (AMD), it can occur secondary to a variety of other diseases. Recent successes with anti-angiogenic therapies suggest that they may outperform other therapies for all types of CNV. As non-AMD-related CNV cases are rare, randomised controlled trials are often not possible. This review compares the less prevalent reports of non-AMD CNV and pools evidence on the success and limitations of a variety of therapies.

show abstract

Intravitreal Bevacizumab for Choroidal Neovascularization Attributable to Pathological Myopia: One-Year Results

Cited by 150 publications

References 28 publications

Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up

Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up

Antiangiogenic Therapy for Ischemic Retinopathies

Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration

Contact Info

Product

Resources

About